Global Endometriosis Market is expected to grow at a CARG of 2.8% during the forecast period 2020-2027

A new research report published by Fior Markets with the title Endometriosis Market by Drug (LNR-IUDs, NSAIDs, Progestins, GnRH Analogues, Oral Contraceptives), Treatment(Pain Management, Hormonal Therapy), Distribution channel(E-commerce, Drugstores, Retail Pharmacies, Hospital Pharmacies, Mail Order Pharmacies), Diagnosis (Laparoscopy, Ultrasound, Hysteroscopy, Pelvic Exam, Sonohysterography, MRI) Region, Global Industry Analysis, Market Size, Share, Growth, Trends, And Forecast 2020 To 2027.

The global Endometriosis market is expected to grow from USD 1.9 billion in 2019 to USD 2.4 billion by 2027, at a CARG of 2.8% during the forecast period 2020-2027.   North America regions is expected have the highest revenue growth, compared to other regions. This is due to the high treatment costs, large number of reproductive population and higher disability losses. The regions like Asia Pacific and Middle East & Africa are slowing the growth in this market, because of lack of treatment, and awareness.

DOWNLOAD FREE SAMPLE REPORT: https://www.fiormarkets.com/report-detail/418386/request-sample

The major players of this market are Bayer AG, Pfizer, Addex Therapeutics, Astellas Pharma, Forendo Pharma, Neurocrine Biosciences, Debiopharm, AbbVie, EndoCeutics, Bayer HealthCare, Euroscreen, Nippon Shinyaku, Kissei Pharmaceutical, Takeda, ElexoPharm and AstraZeneca.

All the players opt for strategies like mergers, joint ventures, acquisition, product development or expansion to sustain in the market.

Astellas Pharma declared development of Opigolix, a receptor antagonist of luteinizing hormone releasing. This product can also be used for oral treatment of endometriosis.

The Drug segment includes LNR-IUDs, NSAIDs, Progestins, GnRH Analogues, Oral Contraceptives. The drugs GrNH A., NSAID’s, Oral Contraceptives are usually used for pain management. The Treatment Segment includes, Pain Management and Hormonal Therapy. The Distribution Channel includes, E-commerce, drugstores, retail pharmacies, hospital pharmacies, and mail order pharmacies. The Diagnosis segment includes, Laparoscopy, Ultrasound, hysteroscopy, Pelvic exam, Sonohysterography, and MRI.

The market driver for endometriosis market is increasing attention towards women’s health.

With the increasing awareness amongst physicians and patients of this condition, the endometriosis market sees a healthy growth. Availability of good medication also contribute to the growth of endometriosis market.  Bayer collaborates with Evotec for trials of phase I small molecules for the treatment of endometriosis and are planning to launch phase III which will help in the global treatment endometriosis market to grow.

The only restrain to the growth of this market is time taken to diagnose the disease, which is very high (7-8 years). And faces challenges like failures in clinical trial.

ACCESS FULL REPORT: https://www.fiormarkets.com/report/endometriosis-market-by-drug-lnr-iuds-nsaids-progestins-gnrh-418386.html

About the report:
The global Endometriosis market is analyzed on the basis of value (USD Billion), volume (K Units), export (K Units), and import (K Units). All the segments have been analyzed on global, regional and country basis. The study includes an analysis of more than 30 countries for each segment. The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The study includes porter’s five forces model, attractiveness analysis, raw material analysis, and competitor position grid analysis.

Customization of the Report:
The report can be customized as per client requirements. For further queries, you can contact us on sales@fiormarkets.com or +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.

Contact Us
Mark Stone
Phone: +1-201-465-4211
Email: sales@fiormarkets.com
Web: www.fiormarkets.com

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.